[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  $akesf $AKESF sees a surge in engagements due to positive clinical trial data in China. Market volatility remains a concern despite the positive news. ### About $akesf A cryptocurrency project. ### Engagements: XXXXX [#](/topic/$akesf/interactions) ---  [Engagements 24-Hour Time-Series Raw Data](/topic/$akesf/time-series/interactions.tsv) **Current Value**: XXXXX **Daily Average**: XXX **1 Week**: XXXXX +21,790% **1 Month**: XXXXX +74% **1-Year High**: XXXXXX on 2025-04-28 **1-Year Low**: X on 2025-06-02 | Social Network | X | | -------------- | - | | Engagements | XXXXX | ### Mentions: X [#](/topic/$akesf/posts_active) ---  [Mentions 24-Hour Time-Series Raw Data](/topic/$akesf/time-series/posts_active.tsv) **Current Value**: X **Daily Average**: X **1 Month**: X -XX% **1-Year High**: XX on 2025-04-30 **1-Year Low**: X on 2025-05-10 | Social Network | X | | -------------- | - | | Mentions | X | ### Creators: X [#](/topic/$akesf/contributors_active) ---  [Creators 24-Hour Time-Series Raw Data](/topic/$akesf/time-series/contributors_active.tsv) X unique social accounts have posts mentioning $akesf in the last XX hours which is up XX% from X in the previous XX hours **Daily Average**: X **1 Month**: X no change **1-Year High**: X on 2025-04-30 **1-Year Low**: X on 2025-05-04 The most influential creators that mention $akesf in the last XX hours | Creator | Rank | Followers | Posts | Engagements | | ------- | ---- | --------- | ----- | ----------- | | [@MarcJacksonLA](/creator/twitter/MarcJacksonLA) | X | XXXXX | X | XXXXX | [View More](/list/creators/$akesf/100) **Top assets mentioned** In the posts about $akesf in the last XX hours [Summit Therapeutics Inc. Common Stock (SMMT)](/topic/$smmt) [One Cash (ONC)](/topic/$onc) [Merck & Co., Inc. (MRK)](/topic/$mrk) **Top topics mentioned** In the posts about $akesf in the last XX hours [$smmt](/topic/$smmt), [china](/topic/china), [$9926hk](/topic/$9926hk), [$14bn](/topic/$14bn), [$psnl](/topic/$psnl), [$onc](/topic/$onc), [$mrk](/topic/$mrk), [coins stablecoin](/topic/coins-stablecoin), [$3m](/topic/$3m) ### Top Social Posts [#](/topic/$akesf/posts) --- Top posts by engagements in the last XX hours *Showing only X posts for non-authenticated requests. Use your API key in requests for full results.* "Great Data out on $SMMT Huge move coming Monday This can see a $XXXXX move" [X Link](https://x.com/trentkelp/status/1979969463895146528) [@trentkelp](/creator/x/trentkelp) 2025-10-19T17:54Z 7570 followers, 1463 engagements "$AKESF $SMMT $ONC $MRK ESMO 2025: Akeso Summit's ivonescimab beats PD-1 in first chemo combo win in first-line NSCLC - Ivonescimab and chemo reduced the risk of progression or death by XX% compared with BeOnes Tevimbra and chemo in first-line squamous NSCLC" [X Link](https://x.com/MarcJacksonLA/status/1979943276066279807) [@MarcJacksonLA](/creator/x/MarcJacksonLA) 2025-10-19T16:10Z 7578 followers, XXX engagements "$SMMT $AKESF ESMO 2025: Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by XX% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China Ivonescimab in Combination with Chemotherapy Is the First Known Regimen to Achieve a Clinically Meaningful Benefit over an anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase X Clinical Trial in 1L NSCLC: Median PFS of XXXXX Months vs. XXXX Months Respectively for Patients Receiving Ivonescimab Plus Chemotherapy vs." [X Link](https://x.com/MarcJacksonLA/status/1979930068978991176) [@MarcJacksonLA](/creator/x/MarcJacksonLA) 2025-10-19T15:18Z 7578 followers, 1897 engagements "$SMMT $AKESF HARMONi-6 Still Chinese data still impressive now in first line NSCLC against Tislelizumab. Still no OS " [X Link](https://x.com/PersimmonTI/status/1979927758089212030) [@PersimmonTI](/creator/x/PersimmonTI) 2025-10-19T15:08Z 10.3K followers, 4964 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
$AKESF sees a surge in engagements due to positive clinical trial data in China. Market volatility remains a concern despite the positive news.
A cryptocurrency project.
Engagements 24-Hour Time-Series Raw Data
Current Value: XXXXX
Daily Average: XXX
1 Week: XXXXX +21,790%
1 Month: XXXXX +74%
1-Year High: XXXXXX on 2025-04-28
1-Year Low: X on 2025-06-02
Social Network | X |
---|---|
Engagements | XXXXX |
Mentions 24-Hour Time-Series Raw Data
Current Value: X
Daily Average: X
1 Month: X -XX%
1-Year High: XX on 2025-04-30
1-Year Low: X on 2025-05-10
Social Network | X |
---|---|
Mentions | X |
Creators 24-Hour Time-Series Raw Data
X unique social accounts have posts mentioning $akesf in the last XX hours which is up XX% from X in the previous XX hours
Daily Average: X
1 Month: X no change
1-Year High: X on 2025-04-30
1-Year Low: X on 2025-05-04
The most influential creators that mention $akesf in the last XX hours
Creator | Rank | Followers | Posts | Engagements |
---|---|---|---|---|
@MarcJacksonLA | X | XXXXX | X | XXXXX |
Top assets mentioned In the posts about $akesf in the last XX hours
Summit Therapeutics Inc. Common Stock (SMMT) One Cash (ONC) Merck & Co., Inc. (MRK)
Top topics mentioned In the posts about $akesf in the last XX hours
$smmt, china, $9926hk, $14bn, $psnl, $onc, $mrk, coins stablecoin, $3m
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"Great Data out on $SMMT Huge move coming Monday This can see a $XXXXX move"
X Link @trentkelp 2025-10-19T17:54Z 7570 followers, 1463 engagements
"$AKESF $SMMT $ONC $MRK ESMO 2025: Akeso Summit's ivonescimab beats PD-1 in first chemo combo win in first-line NSCLC - Ivonescimab and chemo reduced the risk of progression or death by XX% compared with BeOnes Tevimbra and chemo in first-line squamous NSCLC"
X Link @MarcJacksonLA 2025-10-19T16:10Z 7578 followers, XXX engagements
"$SMMT $AKESF ESMO 2025: Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by XX% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China Ivonescimab in Combination with Chemotherapy Is the First Known Regimen to Achieve a Clinically Meaningful Benefit over an anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase X Clinical Trial in 1L NSCLC: Median PFS of XXXXX Months vs. XXXX Months Respectively for Patients Receiving Ivonescimab Plus Chemotherapy vs."
X Link @MarcJacksonLA 2025-10-19T15:18Z 7578 followers, 1897 engagements
"$SMMT $AKESF HARMONi-6 Still Chinese data still impressive now in first line NSCLC against Tislelizumab. Still no OS "
X Link @PersimmonTI 2025-10-19T15:08Z 10.3K followers, 4964 engagements
/topic/$akesf